XNW29016

· Evopoint Biosciences Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XNW29016, covering 2025-06-06 to 2025-06-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment [Phase 1, Phase 2]

See pricing